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Background: Methotrexate (MTX) eradicates leukemic cells by disrupting de novo nucleotide biosynthesis and DNA
replication, resulting in cell death. Since its introduction in 1947, MTX-containing chemotherapeutic regimens have proven
instrumental in achieving curative effects in acute lymphoblastic leukemia (ALL). However, drug resistance phenomena
pose major obstacles to efficacious ALL chemotherapy. Moreover, clinically relevant molecular mechanisms underlying
chemoresistance remain largely obscure. Several alterations in MTX metabolism, leading to impaired accumulation of this
cytotoxic agent in tumor cells, have been classified as determinants of MTX resistance. However, the relation between
MTX resistance and long-term clinical outcome of ALL has not been shown previously.
Methods: We have collected clinical data for 235 childhood ALL patients, for whom samples taken at the time of
diagnosis were also broadly characterized with respect to MTX resistance. This included measurement of concentrations
of MTX polyglutamates in leukemic cells, mRNA expression of enzymes involved in MTX metabolism (FPGS, FPGH, RFC,
DHFR, and TS), MTX sensitivity as determined by the TS inhibition assay, and FPGS activity.
Results: Herein we demonstrate that higher accumulation of long-chain polyglutamates of MTX is strongly associated
with better overall (10-year OS: 90.6 vs 64.1 %, P = 0.008) and event-free survival (10-year EFS: 81.2 vs 57.6 %, P = 0.029) of
ALL patients. In addition, we assessed both the association of several MTX resistance-related parameters determined
in vitro with treatment outcome as well as clinical characteristics of pediatric ALL patients treated with MTX-containing
combination chemotherapy. High MTX sensitivity was associated with DNA hyperdiploid ALL (P < 0.001), which was linked
with increased MTX accumulation (P = 0.03) and elevated reduced folate carrier (RFC) expression (P = 0.049) in this subset
of ALL patients. TEL-AML1 fusion was associated with increased MTX resistance (P = 0.023). Moreover, a low accumulation
of MTX polyglutamates was observed in MLL-rearranged and TEL-AML1 rearranged ALL (P < 0.05).
Conclusions: These findings emphasize the central role of MTX in ALL treatment thereby expanding our understanding
of the molecular basis of clinical differences in treatment response between ALL individuals. In particular, the identification
of patients that are potentially resistant to MTX at diagnosis may allow for tailoring novel treatment strategies to
individual leukemia patients.
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The treatment outcome of pediatric acute lymphoblastic
leukemia (ALL) has greatly improved over the past seven
decades with the current regimens resulting in a 5-year
event-free survival (EFS) of around 80 % [1–3]. This
impressive improvement has been largely attributed to
novel prognostic factors, including cytogenetic abnor-
malities such as TEL-AML1 and E2A-PBX1 gene fusions
associated with good prognosis as well as MLL gene re-
arrangements that confer unfavorable prognosis [4, 5].
Yet, the high cure rates achieved with current treatment
protocols are still paralleled by approximately 20 % risk
of relapse, which is consequently associated with poor
prognosis [2, 3]. The emergence of relapse is largely at-
tributable to drug resistance phenomena of leukemic
cells. Thus, further advances in understanding the mo-
lecular basis underlying these drug resistance phenomena
as well as accurate prediction of chemotherapy resistance
prior to drug treatment may pave the way to overcoming
chemoresistance.
Historically, one of the backbones of contemporary ALL
treatment is the folate antimetabolite—methotrexate
(MTX) [6]. Folates are essential enzyme cofactors involved
in one-carbon metabolism, which includes several cellular
biosynthetic pathways including thymidylate and de novo
purine biosynthesis, amino acid metabolism, and mito-
chondrial protein synthesis [7]. Antifolates potently inhibit
several folate-dependent enzymes engaged in nucleotide
biosynthesis, which leads to cessation of DNA replication
eventually resulting in cell death [6]. High-dose (HD)-
MTX is used as part of the central nervous system (CNS)-
directed therapy (intrathecal MTX), and MTX is an essen-
tial component of the maintenance treatment [1]. MTX is
predominantly taken up into cells via the reduced folate
carrier (RFC/SLC19A1), and in the case of HD-MTX
treatment, also by passive diffusion across cellular mem-
branes, at least to some extent [8, 9]. Upon entry into the
cytoplasm, MTX undergoes polyglutamylation—a unique
metabolic conversion catalyzed by folylpolyglutamate syn-
thetase (FPGS) [9]. This polyglutamylation, which is based
on the sequential addition of multiple glutamate residues
to the γ-carboxyl group of both folates and MTX, ensures
efficient intracellular retention as well as sustains and en-
hances target enzyme inhibition [10–12]. The main targets
of polyglutamylated MTX are dihydrofolate reductase
(DHFR—also inhibited by MTX monoglutamates), thy-
midylate synthase (TS), and several enzymes involved in
purine synthesis [9]. On the other hand, a lysosomal
glycoprotein—folylpolyglutamate hydrolase (FPGH)—can
counteract polyglutamylation, thereby increasing the ef-
flux of MTX by the efflux transporters of the ATP-
binding cassette superfamily including for example
ABCC1 and ABCG2 [9, 13, 14]. Overall, the intracellular
accumulation of MTX polyglutamates in leukemic cellsproved to be an important determinant of the antileukemic
activity of MTX in childhood ALL patients in vivo [15–17].
At the same time, high concentration of long-chain but not
total MTX polyglutamates was associated with inhibition of
de novo purine synthesis [15]. Consequently, a spectrum of
alterations in MTX metabolism resulting in its decreased
cellular accumulation has been identified to induce MTX
resistance and compromise its curative effect. MTX
resistance has been attributed to inactivating mutations or
down-regulation affecting the RFC gene as well as
increased levels of DHFR and TS enzymes together
with mutations that decrease their affinity for antifo-
lates [8, 9, 18–21]. In addition, different polymorphisms
in RFC, TS, and DHFR were previously reported, several
of which were related to increased risk of relapse [22–24].
The cytotoxic effect elicited by MTX is also largely influ-
enced by FPGS activity. Consequently, loss of FPGS func-
tion is a well established mechanism of resistance to MTX
and other polyglutamylation-dependent antifolates in
leukemic cells [17, 25–28]. Differential MTX sensitivity
was shown to be associated with several cytogenetic ab-
normalities. Precursor B cell ALL displaying TEL-AML1
or E2A-PBX1 gene fusions were characterized by de-
creased levels of MTX polyglutamates as compared to
precursor B cell ALL with normal karyotype [16], while
patients with hyperdiploid karyotype were highly sensitive
to MTX [29, 30]. Next, to its own cytotoxic effect, MTX is
also important in the metabolism of other chemothera-
peutics, such as mercaptopurine, used routinely in ALL
treatment. MTX was shown to promote the conversion of
mercaptopurine to one of its active metabolites—thiogua-
nine nucleotides [31, 32]—of which high concentration in
leukemic cells was associated with increased EFS in
leukemia patients [33]. Therefore, it is imperative to
characterize the extent of resistance to this important
chemotherapeutic as well as the mechanisms underlying
this phenomenon.
The aim of the current study was therefore to deter-
mine which parameters of MTX resistance are related to
the long-term clinical outcome in childhood ALL pa-
tients treated with combination chemotherapy. Towards
this goal, we have determined a range of in vitro param-
eters associated with MTX resistance in a large cohort
of pediatric ALL patients and subsequently assessed
their relation with treatment outcome as well as with
clinical characteristics.
Results
The association of ex vivo MTX resistance and the clinical
outcome
To assess the relevance of MTX resistance in pediatric
ALL, we determined several ex vivo parameters character-
izing MTX metabolism in leukemic blasts of ALL patient
specimens. This primarily included the measurement of
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as well as long-chain (4–6 glutamate residues) MTX
polyglutamates and the extent of TS inhibition (thymi-
dylate synthase inhibition assay (TSIA)). For the TSIA
parameter, we used both a continuous (TSIA cont.) and
a short-term (TSIA short) exposure to MTX, followed
by a drug-free period. TSIA cont. represents the overall
ability of cells to accumulate MTX, while TSIA short
enables the efflux of MTX during the drug-free period
and hence rather points to the polyglutamylation cap-
acity of the cells. This approach reliably reflects MTX
sensitivity of leukemic blasts [34]. In addition, FPGSFig. 1 Kaplan–Meier analysis of the accumulation of MTX polyglutamates a
patients. Each survival curve is labeled with the OS rates at 10 years and th
used were: 1935 pmol/109 cells for total accumulation of MTX polyglutama
pmol MTX-Glu2 formed/h/10
6 cells for FPGS activityactivity and mRNA expression of enzymes and proteins
involved in MTX metabolism and transport were deter-
mined including DHFR, TS, FPGS, FPGH, and RFC. The
abovementioned parameters were determined in a co-
hort of 235 samples derived from pediatric ALL patients
at diagnosis. The patients under study were enrolled in
several treatment protocols. The proportion of patients
assigned to specific protocols along with their clinical
characteristics is listed in Additional file 1: Table S1.
Due to logistic challenges and leukemic blast number
limitations, none of the MTX-related parameters could
be measured in all the patients in our cohort. Therefore,nd FPGS activity in relation to overall survival (P logrank) of total ALL
e number of patients included in each subgroup. The cut-off values
tes, 1000 pmol/109 cells for long-chain MTX polyglutamates and 0.35
Fig. 2 Kaplan–Meier analysis of the accumulation of MTX polyglutamates in relation to event-free survival (P logrank). Each survival curve is
labeled with the EFS rates at 10 years and the number of patients included in each subgroup. The cut-off values used were 1935 pmol/109 cells
for total accumulation of MTX polyglutamates and 1000 pmol/109 cells for long-chain MTX polyglutamates
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varied considerably for the different parameters and the
number of patients used for each measurement as listed
in the various tables.
The prognostic value of MTX resistance associated pa-
rameters was assessed with respect to long-term overall
survival (OS) as well as EFS of childhood ALL patients.
We identified three MTX-related variables that were sig-
nificantly associated with OS in Kaplan–Meier analysis
(Fig. 1). Higher levels of both the total concentration of
cellular MTX as well as long-chain MTX polyglutamates
were predictive of a better outcome. A 10-year OS
reached 89.7 % in patients with high concentrations of
total MTX polyglutamates and 90.6 % in case of long-
chain MTX polyglutamates, compared to 64 % in patients
with low levels of these MTX metabolites (P = 0.018 for
total concentration and P = 0.008 for long-chain MTX
polyglutamates, respectively). Consistently, higher FPGS
activity was also predictive of a better OS (P = 0.039). For
EFS, only the accumulation of long-chain MTX polygluta-
mates was a significant predictor of a better outcome
(Fig. 2; P = 0.029). The total concentration of MTX
showed a similar trend, although it did not reach signifi-
cance (Fig. 2, P = 0.055). The univariate Cox regression
model further confirmed the concentration of both
long-chain (EFS: HR = 2.61, P = 0.035, OS: HR = 4.44,
P = 0.015) and total MTX polyglutamates (EFS: HR =
2.29, P = 0.062, OS: HR = 3.8, P = 0.028) as the stron-
gest prognostic variables (Table 1 and Additional file 1:
Table S2). Due to the large heterogeneity of treatment
protocols applied in therapy of the patients under
study, we performed our analyses both with and with-
out the correction for the treatment protocol. In this
analysis, the concentration of the long-chain MTX
polyglutamates was still significantly associated with
OS (HR = 3.82, P = 0.03) but not with EFS (HR = 2.23,P = 0.084), whereas the levels of total MTX polygluta-
mates were not significant for both the EFS and OS (EFS:
HR = 1.73, P = 0.232, OS: HR = 2.57, P = 0.125). Intri-
guingly, low RFC mRNA expression was a significant pre-
dictor of a longer EFS when corrected for the treatment
protocol (HR = 0.15, P = 0.009). Trends observed for the
concentration of both the total as well as long-chain MTX
polyglutamates in the whole patient cohort were also ap-
parent when precursor B cell ALL patients were analyzed
separately (data not shown), while the numbers of T cell
ALL patients were too low for further analysis.
Next, the independent prognostic values of the con-
centration of total as well as long-chain MTX polygluta-
mates were examined in the multivariate Cox regression
model, in combination with clinical factors significantly
associated with the EFS (white blood cell count—WBC,
age, and CNS involvement—see Additional file 1: Tables
S3 and S4) and OS (WBC, age, CNS involvement,
lineage, and DNA index). Neither of the parameters
tested had independent prognostic value in the multi-
variate analysis of EFS (Additional file 1: Table S5), both
with (HR = 1.65, P = 0.292 for the total MTX polygluta-
mates, HR = 2.16, P = 0.112 for the long-chain MTX
polyglutamates) and without the correction for treat-
ment protocol (HR = 1.9, P = 0.170 for the total MTX
polyglutamates, HR = 2.33, P = 0.073 for the long-chain
MTX polyglutamates). RFC mRNA expression showed
a significant association with OS in the multivariate
analysis both with (HR = 0.18, P = 0.025) and without
(HR = 0.13, P = 0.026) the correction for the treatment
protocol. As in the univariate analysis, low RFC ex-
pression was predictive of a better OS which is the op-
posite of what was expected. Neither the accumulation
of the total nor the long-chain MTX polyglutamates
showed significant association with the OS (Additional
file 1: Table S6).
Table 1 Results of univariate Cox regression model of MTX resistance-related variables in relation to event-free survival
Not corrected for protocols Corrected for protocols
N Hazard ratio (95 % CI) P value N Hazard ratio (95 % CI) P value
TSIA short (cut-off 1.44 μM)
Low 79 1.00 73 1.00
High 23 1. 39 (0.67–2.89) 0.374 22 1.34 (0.60–3.01) 0.477
TSIA continuous (cut-off 0.035 μM)
Low 25 1.00 22 1.00
High 75 1.19 (0.54–2.60) 0.671 70 1.3 (0.53–3.18) 0.567
MTX-Glu1–6 accumulation (cut-off 1935 pmol/109 cells)
High 29 1.00 29 1.00
Low 79 2.29 (0.96–5.45) 0.062 72 1.73 (0.70–4.27) 0.232
MTX-Glu4–6 accumulation (cut-off 1000 pmol/109 cells)
High 32 1.00 32 1.00
Low 59 2.61 (1.07–6.36) 0.035* 56 2.23 (0.90–5.57) 0.084
DHFR mRNA (cut-off 3.74)
High 27 1.00 27 1.00
Low 18 1.50 (0.50–4.47) 0.466 18 1.16 (0.37–3.67) 0.796
TS mRNA (cut-off 10)
Low 34 1.00 33 1.00
High 12 0.77 (0.21–2.81) 0.696 12 0.78 (0.21–3.22) 0.781
FPGS mRNA (cut-off 4.13)
High 19 1.00 19 1.00
Low 23 1.17 (0.36–3.83) 0.798 22 0.58 (0.16–2.18) 0.421
FPGH mRNA (cut-off 3.17)
High 16 1.00 15 1.00
Low 18 1.18 (0.32–4.40) 0.805 18 0.80 (0.19–3.33) 0.764
RFC mRNA (cut-off 0.86)
High 19 1.00 19 1.00
Low 25 0.70 (0.23–2.19) 0.544 24 0.36 (0.10–1.32) 0.123
FPGS activity (cut-off 0.35)
High 48 1.00 48 1.00
Low 12 2.32 (0.79–6.80) 0.125 11 2.61 (0.88–7.76) 0.084
TSIA continuous and short-term exposure (TSIA short) are expressed as the concentration of MTX (in μM) necessary to inhibit 50 % of the TS activity (TSI50)
compared to the controls incubated without MTX (in triplicate); the concentration of MTX polyglutamates (MTX-Glu1–6 and MTX-Glu4–6) is expressed as pmol
MTX-Glun/10
9 cells; mRNA expression of folate enzymes is expressed as ratio normalized to β-actin; FPGS activity is expressed as pmol MTX-Glu2 formed/h/10
6 cells. The
asterisk denotes significant associations
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To substantiate the associations found in the clinical
outcome analysis, we performed a more in-detail
characterization of MTX resistance in the patient cohort
under study. Since, precursor B cell ALL and T cell ALL
have a different MTX response, we first compared the
distribution of the MTX-resistance parameters between
these two subtypes of ALL (Table 2). Indeed, our results
support previously reported findings in a patient group
partially overlapping with the currently analyzed cohort[17, 34, 35]. Accordingly, precursor B cell ALL patient
specimens showed higher MTX sensitivity than T cell
ALL samples, as determined by lower median TSI50 values
for the short-term exposure (3.9-fold difference in the
median, P < 0.001), as well as higher accumulation of
both total and long-chain MTX polyglutamates (1.9-fold
and 3.3-fold, respectively, P < 0.001). These differences
were paralleled by higher mRNA expression (2.6-fold,
P = 0.008) and enzyme activity (5.6-fold, P < 0.001) of
FPGS in precursor B cell ALL as well as elevated levels
Table 2 MTX resistance-related variables in precursor B and T
cell ALL
Precursor B cell ALL T cell ALL
N Median (range) N Median (range) P value
TSIA cont. 85 0.058 (0.01–0.76) 30 0.062 (0.01–0.22) 0.595
TSIA short 87 0.37 (0.16–12.97) 30 1.44 (0.16–40.0) <0.001
MTX-Glu1–6 97 1210 (120–4838) 31 630 (314–1943) <0.001
MTX-Glu4–6 83 856 (80–3190) 25 260 (0–843) <0.001
DHFR mRNA 37 3.86 (0.27–55.06) 17 12.42 (1.48–34.11) <0.001
TS mRNA 37 2.64 (0.24–23.04) 18 10.26 (1.64–25.04) <0.001
FPGS mRNA 32 6.26 (1.12–39.64) 20 2.39 (0.52–17.20) 0.008
FPGH mRNA 27 2.12 (0.16–18.00) 16 4.83 (0.18–27.65) 0.196
RFC mRNA 35 0.89 (0.24–6.90) 20 0.79 (0.23–4.79) 0.668
FPGS activity 57 1.01 (0.03–11.33) 16 0.18 (0.02–1.57) <0.001
P value is determined by the Mann–Whitney U test; TSIA continuous (TSIA
cont.) and short-term exposure (TSIA short) are expressed as the concentration
of MTX (in μM) necessary to inhibit 50 % of the TS activity (TSI50) compared to
the controls incubated without MTX (in triplicate); the concentration of
MTX polyglutamates (MTX-Glu1–6 and MTX-Glu4–6) are expressed as pmol
MTX-Glun/10
9 cells; mRNA expression of folate enzymes is expressed as ra-
tio normalized to β-actin; FPGS activity is expressed as pmol MTX-Glu2
formed/h/106 cells
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3.9-fold, respectively, both P < 0.001).
Next, in order to determine which variables strongly
influence MTX resistance in ALL patients, we exam-
ined the correlation between cellular levels of MTX
polyglutamates, activities, and mRNA expression levels
of MTX metabolic enzymes with in vitro MTX sensi-
tivity as determined by the TSIA. In line with previousTable 3 Correlation of the TSIA assay (continuous and short exposu
expression
Precursor B cell ALL
TSIA cont. TSIA short
MTX-Glu1–6
Correlation coefficient −0.547* −0.495*
P value <0.001 <0.001
Number of patients 64 58
MTX-Glu4–6
Correlation coefficient −0.494* −0.503*
P value <0.001 <0.001
Number of patients 54 50
TS mRNA
Correlation coefficient 0.591 0.678*
P value 0.056 0.045
Number of patients 11 9
P value was estimated using Spearman’s Rho test; TSIA continuous (TSIA cont.) and
μM) necessary to inhibit 50 % of the TS activity (TSI50) compared to the controls inc
(MTX-Glu1–6 and MTX-Glu4–6) is expressed as pmol MTX-Glun/10
9 cells; TS mRNA
significant (P < 0.05) associationsfindings [34], both the TSIA results based on continuous
and the short-term MTX exposure correlated with con-
centrations of total (TSIA continuous: R = −0.432 and
TSIA short-term: R = −0.524, P < 0.001) and long-chain
MTX polyglutamates (Table 3, R = −0.399, P = 0.001
and R = −0.568, P < 0.001) as well as with the TS
mRNA expression (TSIA continuous: R = 0.466, P =
0.033 and TSIA short-term: R = 0.693, P = 0.001). Simi-
lar correlations were obtained when precursor B cell
patients were examined separately. Weaker and non-
significant correlations were found in T cell ALL, sug-
gesting that there might be a substantial difference
between the factors determining MTX resistance in
precursor B cell and T cell leukemia. To formally test
whether the strength of association between TSIA and
MTX polyglutamates or TS mRNA expression differed
between B cell and T cell leukemia, we used a linear re-
gression model that included an interaction between
the level of MTX polyglutamates and the lineage. No
significant difference in association between the con-
centration of MTX polyglutamylates and both the
continuous and short-term TSIA was found between
the precursor B cell and T cell ALL (data not shown).
Intriguingly, the accumulation of both total and long-
chain MTX polyglutamates correlated with FPGS activity
but not with its mRNA levels (Table 4). This association
was observed for the whole cohort as well as for precursor
B cell ALL alone. Consequently, FPGS mRNA expression
did not correlate with FPGS activity (P = 0.125 for
the whole cohort, P = 0.75 for precursor B cell ALL,
and P = 0.544 for T cell ALL).re) with accumulation of MTX polyglutamates and TS mRNA
T cell ALL Total ALL
TSIA cont. TSIA short TSIA cont. TSIA short
−0.094 −0.128 −0.432* −0.524*
0.685 0.612 <0.001 <0.001
21 18 85 76
−0.258 0.046 −0.399* −0.568*
0.336 0.875 0.001 <0.001
16 14 70 64
0.139 0.483 0.466* 0.693*
0.701 0.187 0.033 0.001
10 9 21 18
short-term exposure (TSIA short) are expressed as the concentration of MTX (in
ubated without MTX (in triplicate); the concentration of MTX polyglutamates
level is expressed as ratio normalized to β-actin. The asterisk denotes
Table 4 Correlation of cellular MTX polyglutamate levels with mRNA expression of FPGS and FPGH as well as FPGS activity
Precursor B cell ALL T cell ALL Total ALL
MTX-Glu1–6 MTX-Glu4–6 MTX-Glu1–6 MTX-Glu4–6 MTX-Glu1–6 MTX-Glu4–6
FPGS mRNA
R −0.168 −0.082 0.345 0.002 0.264 0.280
P value 0.456 0.724 0.176 0.994 0.104 0.104
Number of patients 22 21 17 14 39 35
FPGH mRNA
R 0.117 0.195 0.366 0.537 0.101 0.045
P value 0.622 0.424 0.219 0.110 0.576 0.817
Number of patients 20 19 13 10 33 29
FPGS activity
R 0.429* 0.419* 0.265 0.05 0.522* 0.533*
P value 0.005 0.01 0.431 0.898 <0.001 <0.001
Number of patients 41 37 11 9 52 46
R and Pvalues were estimated using Spearman’s Rho test; the concentration of MTX polyglutamates (MTX-Glu1–6 and MTX-Glu4–6) is expressed as pmol
MTX-Glun/10
9 cells; mRNA expression of folate enzymes is expressed as ratio normalized to β-actin; FPGS activity is expressed as pmol MTX-Glu2 formed/h/10
6 cells. The
asterisk denotes significant (P < 0.05) associations
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Next, we examined the possible association of MTX re-
sistance with the hyperdiploid karyotype as well as three
other recurrent cytogenetic abnormalities seen in ALL:
MLL rearrangements, TEL-AML1, and E2A-PBX1. We
found that blasts of hyperdiploid ALL patients were
significantly more sensitive to MTX than blasts from
non-hyperdiploid ALL patients (Fig. 3), both in the con-
tinuous and the short-term TSIA (P < 0.001). Consistent
with previous reports [30, 36], the leukemic blasts of
these patients accumulated significantly higher levels of
total MTX and in the same time displayed elevated RFC
mRNA levels, confirming that increased uptake of MTX
contributes to MTX hypersensitivity observed in this
group.
Similarly, the analyzed cytogenetic subtypes of ALL
showed several associations with MTX resistance-related
parameters (Table 5). In line with findings from others
[16], we established that TEL-AML1 fusion results in
lower accumulation of both total and long-chain MTX
polyglutamates (2.2-fold, P = 0.013 and 2.8-fold, P = 0.007,
respectively). In addition, these patients showed higher
TSI50 values for both continuous and short-term exposure
(3.3-fold, P = 0.023 and 2.9-fold P = 0.06, respectively).
Interestingly, ALL patients with MLL rearrangements also
displayed lower accumulation of total and long-chain
MTX polyglutamates (3.6-fold, P = 0.005 and 4.3-fold,
P = 0.012, respectively), however this was not paralleled
by elevated TSI50 values. No significant correlations were
observed for patients harboring the E2A-PBX1 nor BCR-
ABL gene fusions, which can partially be explained by the
small patient numbers in both groups.Discussion
In the current study, which used multiple parameters as-
sociated with MTX sensitivity, we demonstrate that the
cellular level of MTX-induced cytotoxicity is an import-
ant determinant of long-term treatment outcome in
childhood ALL. We showed that accumulation of long-
chain MTX polyglutamates was the strongest MTX
resistance-associated variable, as reflected by its signifi-
cant association with both OS and EFS in the analyzed
patient cohort. Our data support and further extend pre-
vious studies documenting better antileukemic effect of
MTX as well as favorable 5-year EFS in childhood ALL
patients, whose leukemic cells accumulated higher levels
of MTX polyglutamates [15, 29, 37]. On the other hand,
a study of the Children’s Oncology Group (COG) sug-
gested that the association between the concentration of
MTX polyglutamates and EFS is abrogated by higher
dose MTX therapy [38]. However, this study involved a
different mode of MTX administration and cut-off levels
for high/low polyglutamate accumulation, which might
have influenced the different outcome of the analysis.
When analyzed in multivariate Cox regression with cor-
rection for established clinical factors (including WBC,
age, CNS involvement, lineage, and DNA index) as co-
variates, the cellular level of long-chain MTX polygluta-
mates was not an independent prognostic factor. This
indicates that despite the important role in ALL treat-
ment response, MTX polyglutamates may not have
additional predictive value to the already existing
models. Surprisingly, low levels of RFC were predictive
of a better overall survival in both univariate and multi-
variate analysis, contradicting previous reports [9, 39].
The relation between RFC mRNA expression and overall
Fig. 3 MTX resistance-related variables that are significantly different in precursor B cell ALL patients with hyperdiploid karyotype compared to
non-hyperdiploid precursor B cell ALL patients. The box plots depict means with standard deviation (P Mann–Whitney U test)
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ment protocol, suggesting that it might be linked to high
doses of MTX used in some treatment protocols. When
examined within each treatment protocol separately, this
association was only observed in patients treated at
DCOG ALL8 protocol, on which patients depending on
the risk group were administered MTX at 2 g/m2 or 5 g/
m2 [40]. In contrast, on COALL protocol ALL-97, for
which this relation was absent, MTX was administered
at 1 g/m2 [2, 41]. This discrepancy may be explained by
the limited number of patients treated with 1 g/m2 in
this cohort (6 patients for COALL-97 and 16 for DCOG
ALL8). Decreased RFC expression as well as mutations
in the RFC gene resulting in less efficient uptake of anti-
folates by tumor cells, have been associated with MTX
resistance [9, 39]. On the other hand, some of the muta-
tions found in the RFC gene were previously reported to
increase the affinity of RFC to folates, resulting in in-
creased intracellular accumulation and competition of fol-
ate with MTX [42]. It is therefore possible that extremely
high RFC expression results in high concentration of
folates in the cells, leading to decreased efficacy of MTX
and worse treatment outcome. Unfortunately, the num-
bers of patients treated on the other protocols for which
RFC mRNA expression data were available were too low
to allow this analysis.Moreover, we show that the lineage as well as a num-
ber of chromosomal abnormalities are associated with
distinct levels of MTX sensitivity. In agreement with
previous analysis in a partially overlapping patient co-
hort as well as in other studies [17, 34, 35], we observed
here elevated accumulation of MTX polyglutamates
together with decreased expression of DHFR and TS
mRNA and consequently higher MTX sensitivity in pre-
cursor B cell ALL, as compared to T cell ALL. The dif-
ference in the accumulation of the long-chain MTX
polyglutamates between these two distinct subtypes of
ALL exceeded that obtained for the total MTX polyglu-
tamates. This observation, together with the FPGS activ-
ity being significantly increased in the precursor B cell
ALL, suggests that differences in MTX response be-
tween the precursor B cell and T cell leukemia are highly
dependent on FPGS activity and consequent MTX poly-
glutamylation. Indeed, a previous study comparing
lineage-based differences in MTX sensitivity in leukemia
cell lines also pointed to the involvement of FPGS activ-
ity and DHFR levels [43]. The importance of the cellular
accumulation of MTX polyglutamates was further cor-
roborated by its association with the TSIA, which was
previously shown to be a good determinant of MTX sen-
sitivity, as reflected by the correlation between the TSIA
results and MTX cytotoxicity [34]. This association was
Table 5 MTX sensitivity and accumulation of MTX polyglutamates in relation to cytogenetic abnormalities
TSIA cont. TSIA short MTX-Glu1–6 MTX-Glu4–6
Normal cytogenetics N 16 23 18 17
Median (range) 0.048 (0.01–0.71) 0.28 (0.16–2.84) 2102 (436–4240) 1514 (209–3190)
MLL-rearranged N 8 6 4 3
Median (range) 0.06 (0.03–0.16) 0.21 (0.16–1.33) 591 (360–1016) 350 (280–443)
P value 0.610 0.896 0.005* 0.012*
BCR-ABL N 4 2 4 2
Median (range) 0.04 (0.03–0.28) – 2088 (360–3721) 1630 (1212–2047)
P value 0.750 0.240 0.712 0.749
TEL-AML1 N 10 9 8 7
Median (range) 0.16 (0.06–0.37) 0.82 (0.54–11.21) 945 (290–2476) 550 (380–1152)
P value 0.023* 0.06 0.013* 0.007*
E2A-PBX1 N 3 3 1 0
Median (range) 0.14 (0.05–0.29) 0.77 (0.57–1.12) – –
P value 0.254 0.157 – –
First, the Kruskal–Wallis analysis of variance was used to compare all the four groups, and variables with the P value above 0.1 were further examined in detail.
The Mann–Whitney U test was used to compare MTX-related variables between each subgroup of ALL patients carrying certain cytogenetic abnormality and
patients displaying normal karyotype as a reference group; TSIA continuous (TSIA cont.) and short-term exposure (TSIA short) are expressed as the concentration
of MTX (in μM) necessary to inhibit 50 % of the TS activity (TSI50) compared to the controls incubated without MTX (in triplicate); the concentration of MTX
polyglutamates (MTX-Glu1–6 and MTX-Glu4–6) is expressed as pmol MTX-Glun/10
9 cells. The asterisk denotes significant (P < 0.05) associations
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cursor B cell ALL alone but not in T cell ALL when ana-
lyzed separately. The linear regression analysis did not
show that the association of cellular MTX polyglutamate
levels with the TSIA is actually different between precur-
sor B cell and T cell leukemia. The apparent differences
between the correlations may be due to a large uncer-
tainty in the estimates for the correlations of the T cell
ALL, which may have been caused by the small sample
size for this subgroup. Taken together, our data indicate
that despite the differences in concentration of MTX
polyglutamates and MTX sensitivity profiles between
precursor B cell and T cell ALL, the accumulation of
MTX polyglutamates is likely an indicator of MTX re-
sistance as determined by the TSIA in both of these ALL
subtypes.
Intriguingly, in parallel to differences in both FPGS
mRNA levels and activity observed between precursor B
cell and T cell ALL, we found no correlation between
FPGS mRNA level and enzyme activity or the concentra-
tion of MTX polyglutamates. This suggests that the level
of FPGS mRNA might not directly translate to its en-
zymatic activity. A strong correlation was previously re-
ported between FPGS mRNA expression and activity in
leukemic cell lines [43]. In fact, our previous finding of
the high propensity of human FPGS gene in ALL speci-
mens to undergo impaired splicing is consistent with the
fact that transcript levels may not correlate at all with
FPGS catalytic activity [28, 44], Wojtuszkiewicz et al. un-
published observations. Moreover, decreased rates of
FPGS mRNA translation affecting its activity werepreviously detected in murine leukemic cell lines se-
lected with another polyglutamylation-dependent antifo-
late—edatrexate [45]. In addition, we have reported that
aberrant FPGS splicing is a potential contributing factor
to the loss of FPGS function, as various FPGS mRNA
splicing alterations were detected in MTX-resistant
leukemic cell lines devoid of FPGS activity as well as in
adult ALL patient samples [28].
MTX sensitivity in the patient cohort under study
differed between several genetic subtypes of precursor B
cell ALL. This included the hyperdiploid patients, dis-
playing high MTX sensitivity associated with increased
RFC expression as well as TEL-AML1 fusion and MLL
rearrangements displaying an increased MTX resistance.
Elevated RFC expression might be caused by an
additional copy of RFC gene-carrying chromosome 21,
which is often observed in hyperdiploid ALL. Our re-
sults support previous findings showing that hyperdi-
ploid patients accumulate higher levels of MTX
polyglutamates associated with elevated RFC expression
[29, 30]. Consequently, this subset of patients responded
favorably to MTX-containing chemotherapy as com-
pared to patients with a non-hyperdiploid karyotype
[37]. Although the remarkable sensitivity of hyperdiploid
ALL cannot be entirely explained by high MTX sensitiv-
ity, the current results as well as observations of others
[29, 30, 37] suggest that it is an important biological fea-
ture contributing to sensitivity of this ALL subtype. Pre-
cursor B cell ALL with TEL-AML1 fusion as well as with
rearrangedMLL gene were associated with lower accumu-
lation of MTX polyglutamates, which in the case of TEL-
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reflected by the TSIA. Precursor B cell ALL carrying either
TEL-AML1 or E2A-PBX1 gene fusions was previously
shown to accumulate decreased levels of MTX polygluta-
mates as compared to precursor B cell ALL which are
devoid of these cytogenetic aberrations [16]. This was
associated with diminished expression of RFC in E2A-
PBX1 ALL and elevated expression of ABCG2—an MTX
efflux transporter—in ALL patients with TEL-AML1 fu-
sion [16]. Decreased RFC activity resulting from transcrip-
tional silencing as well as mutations and allele loss was
previously reported as the cause of antifolate resistance in
several tumor types, including leukemia, breast cancer,
and osteosarcoma [19–21]. Similar overexpression of ABC
transporters is an established mechanism of antifolate re-
sistance [9, 13, 46]. Moreover, another study suggests that
both TEL-AML1 and E2A-PBX1 gene fusions downregu-
late FPGS expression by interacting with its promoter re-
gion [47, 48]. Interestingly, TEL-AML1 and E2A-PBX1 are
generally associated with a relatively good prognosis, as
opposed to patients harboring rearranged MLL gene [4],
which can be explained by the differences in sensitivity to
other chemotherapeutics between these ALL subtypes [5].
The numbers of ALL patients displaying these cytogenetic
abnormalities for which MTX sensitivity-associated vari-
ables were measured was very limited in this study. Hence,
we were not able to evaluate the role of particular triso-
mies (i.e., trisomy 21) across the patients with hyperdi-
ploid karyotype or the analyzed cytogenetic abnormalities.
Therefore, these associations should be further addressed
in large future studies. However, the current data suggest
that TEL-AML1, E2A-PBX1, and MLL-rearranged ALL
may benefit from courses with high-dose MTX, partly
overcoming the polyglutamylation and transport defects
[16, 18].
One of the major limitations of the current study was
the low numbers of patients for which particular param-
eters were recorded. This especially influenced analyses
in various ALL groups, such as cytogenetic subtypes,
where the patient numbers were extremely low. More-
over, patients included in this study were treated on di-
verse protocols with distinct MTX administration doses.
This issue, however, was addressed in the statistical ana-
lysis by including the treatment protocol as a covariate.
Finally, the lack of MTX-related toxicity data limited our
insight into the associations of particular MTX resistance-
related parameters and the clinical outcome of ALL
patients. These issues should be carefully considered in
future studies.
Conclusions
Taken together, our study clearly shows that the low cellu-
lar level of long-chain polyglutamates of MTX is an im-
portant predictor of MTX resistance and is associatedwith dismal therapeutic outcome. Its additional prognostic
value warrants further investigation in larger studies
using more up-to-date treatment regimens. As MTX re-
mains one of the mainstays of contemporary ALL treat-
ments, expanding our understanding of its contribution
to the treatment outcome is of supreme therapeutic
value. In particular, the identification of patients that
are potentially resistant to MTX at start of the treat-
ment may allow for tailoring novel treatment strategies
to individual leukemia patients in the context of com-
bination chemotherapy.Materials and methods
ALL patients
We analyzed a total of 235 newly diagnosed (see Additional
file 1: Table S1 for patient characteristics), untreated
pediatric ALL patients treated on Dutch Childhood
Oncology Group (DCOG N = 125) protocols ALL6–ALL9
[40, 49], German Co-operative ALL study group (COALL
N = 93) protocols 92–97 [2, 41] and Nordic Society of
Paediatric Haematology and Oncology (NOPHO N = 17)
protocols ALL-92–ALL-2000 [50]. All patients (or parents
or legal guardians of patients) have provided a written in-
formed consent.
Immunophenotyping and DNA index flow cytometry
were performed at reference laboratories of the partici-
pating groups; patient characteristics were collected by
the study centers.
For all patients, leukemic cells freshly obtained from
the bone marrow or peripheral blood of ALL patients
at diagnosis were isolated within 48 h of sampling as
described previously [51]. When necessary, contaminat-
ing normal cells were removed by monoclonal anti-
bodies linked to magnetic beads as described previously
[52]. All samples contained >80 % leukemic blasts with
the majority of samples reaching blast percentages
around 90 % (only 11 out of 235 patient samples con-
tained <85 % blasts), as determined by cytospin prepa-
rations stained with May-Grunwald-Giemsa (Merck,
Darmstadt, Germany).
This study was approved by the Local Ethics Committee
VUmc. Date of approval: December 5, 2000 (file number
TJFS/bz2568a).In situ thymidylate synthase inhibition assay
The TSIA was used to measure in vitro efficacy of MTX
to inhibit TS, which is known to determine cytotoxicity
in MTX exposed cells. Inhibition of TS was determined
in whole cells by measuring the TS-catalyzed conversion
of 3H-dUMP to dTMP and 3H2O, as described previ-
ously [34]. Two conditions were used: a continuous 21-h
incubation or a short 3-h exposure, followed by an 18-h
drug-free period. Data are expressed as the concentration
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compared to the controls incubated without MTX (in
triplicate) [34, 53].
MTX accumulation and polyglutamylation
Ten million leukemic cells were incubated for 24 h with
1 μM [3′, 5′, 7-3H]-MTX (Moravek Biochemicals; final
specific activity 2 Ci/mmol) in a 5-ml culture medium,
as described previously [17]. After washing, samples
were counted for radioactivity, cell number, and viability.
The remaining suspension was centrifuged, and the cell
pellet was used for measurement of polyglutamates
using high-performance liquid chromatography on an
anion exchange column as described previously [17, 53].
The data are expressed as pmol MTX-Glun/10
9 cells.
Total MTX polyglutamates included MTX associated
with 1 up to 6 glutamate residues, while long-chain MTX
polyglutamates corresponded to MTX associated with 4
up to 6 glutamate residues.
RNA extraction, reverse transcription, and quantitative
PCR assay
Freshly isolated cells were washed twice in RPMI
(Gibco) containing 2 % fetal calf serum, followed by
lysis in 1 ml RNAzol. Next, the samples were frozen in
liquid nitrogen and stored at −80 °C until further pro-
cessing. RNA extraction was performed according to
manufacturer’s instructions with previously described
adjustments [35]. Competitive template PCR was per-
formed as described previously [35].
FPGS activity assay
The FPGS activity assay was performed as described
previously [17]. Briefly, the reaction was carried out in
crude cell extracts employing a 2-h incubation with a
final concentration of 250 μM MTX and 4 mM [3H]-L-
glutamic acid at 37 °C, which was next terminated with
ice-cold glutamic acid. The resulting MTX-[3H]-Glu2
was separated from unreacted [3H]-L-glutamic acid by
reverse-phase column chromatography and quantified as
described previously [17].
Statistical analysis
All statistical analyses were performed using the IBM
SPSS Statistics 20 software. The Mann–Whitney U test
was used to compare the levels of MTX resistance-
related variables between different subgroups of ALL
patients, while Spearman’s Rho test and linear regression
were applied to assess correlations. Kaplan–Meier ana-
lysis and Cox regression were used in the analysis of EFS
as well as OS of the patients. The cut-off values for sur-
vival analysis were selected based on literature (clinical
factors) [2, 40, 41, 49, 50]. For MTX-related variables, if
the distribution was bimodal, we chose the cut-off valuemidway between the two modes of the distributions;
otherwise, we used the median as a cut-off. Kaplan–
Meier analysis and Cox regression were used for testing
associations between MTX resistance-related variables
and event-free (defined as time from complete remission
to an event) as well as overall survival of the patients.
Events considered in event-free survival were relapse and
death. MTX resistance-related variables which showed
significant impact on survival in the univariate analysis
(P < 0.05 at two-sided testing) were added to a multivari-
ate Cox regression model with identified prognostic clin-
ical factors in order to assess their added prognostic value.
As different protocols were used with different patients,
additional analyses were performed in which we corrected
for the protocol used by including protocol as an add-
itional independent variable in the Cox regression model.
Additional file
Additional file 1: Patient characteristics and supplemental survival
analysis. Table S1. Clinical characteristics of pediatric ALL patients
included in this study. Table S2. Results of univariate Cox regression
model of MTX resistance related variables in relation to overall survival.
Table S3. Treatment outcome (EFS) in the whole cohort according to
presenting features (not corrected for the treatment protocol). Table S4.
Treatment outcome (EFS) in the whole cohort according to presenting
features (corrected for the treatment protocol). Table S5. Results of
multivariate Cox regression model of MTX resistance related variables in
relation to event-free survival. Table S6. Results of multivariate Cox regression
model of MTX resistance related variables in relation to overall survival.
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